PHT Corporation’s Market Leading LogPad(R) and StudyWorks(TM) ePRO Solutions Used in Sanofi Pasteur’s Phase II Study of New Clostridium Difficile Vaccine

BOSTON--(BUSINESS WIRE)--PHT Corporation announced that Sanofi Pasteur is using PHT’s LogPad® System and StudyWorksTM online portal for a Phase II trial to develop a vaccine against the Clostridium difficile bacterium. PHT is the leading provider of ePRO solutions used in pharmaceutical and biotechnology clinical trials worldwide. Sanofi Pasteur, a world leader in the vaccines industry, is the vaccines division of the sanofi-aventis Group.